Skip to main content

Tenaya Therapeutics, Inc.

TNYA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001858848

In the last 90 days, Tenaya Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 101 institutions reported holding it in 13F filings for Q2 2026, worth $39.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tenaya Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $21.0K in total
Insiders trading
2
Net value
−$21.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tenaya Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tenaya Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ali FarazChief Executive Officer539,782Sep 11, 20266
Tingley WhittemoreChief Medical Officer263,073Sep 11, 20266
Hyllengren Eric JChief Financial Officer–Jul 14, 20261
Williams R SandersDirector–May 29, 20261
Walsh Jeffrey T.Director–May 29, 20261
Parschauer Karah HerdmanDirector–May 29, 20261
Lee JuneDirector–May 29, 20261
Stehman-Breen CatherineDirector–May 29, 20261
Srivastava DeepakDirector372,435IndirectMay 29, 20261
Burroughs Amy L.Director–May 29, 20261
Higa TomohiroSVP, Finance118,267May 19, 20264
Svennilson Peter10% Owner0IndirectFeb 26, 20263
Kutzkey Tim10% Owner0IndirectFeb 26, 20263
Column Group III-A, LP10% Owner0IndirectFeb 26, 20263
Column Group III, LP10% Owner0IndirectFeb 26, 20263
Column Group III GP, LP10% Owner0IndirectFeb 26, 20263
Column Group Opportunity III, LP10% Owner0IndirectFeb 26, 20263
TCG Opportunity III GP, LLC10% Owner0IndirectFeb 26, 20263
Column Group Opportunity III GP, LP10% Owner0IndirectFeb 26, 20263
Goeddel David VDirector, 10% Owner49,313,559IndirectMay 30, 20250
Saito ChihiroSVP, Accounting and Fin. Ops.60,983Nov 18, 20240
Hoey TimothyChief Scientific Officer245,346Mar 6, 20240
Patterson Leone DChief Fin. and Bus. Officer95,755Feb 27, 20240
Chen Jin-LongDirector–Jun 12, 20230
Casdin Capital, LLCDirector6,078,860IndirectNov 25, 20220
Casdin EliDirector6,078,860IndirectNov 25, 20220
Casdin Partners Master Fund, L.P.10% Owner361,969IndirectAug 4, 20210
Casdin Private Growth Equity Fund, L.P.10% Owner361,969IndirectAug 4, 20210
Casdin Private Growth Equity Fund GP, LLC10% Owner361,969IndirectAug 4, 20210
Kang JeenJooDirector25,000Aug 4, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 4, 2021 (view filing)Aug 31 dayCasdin EliDirector, 10% OwnerPPurchase+850.0K$15.00+$12.8M+35.8%3.22M after
Aug 4, 2021 (view filing)6:33 PM ETAug 31 dayCasdin Capital, LLC and 3 others10% OwnerPPurchase+850.0K$15.00+$12.8M+35.8%3.22M afterDuplicate filing
Apr 28, 2022 (view filing)Apr 262 daysHoey TimothyChief Scientific OfficerSSale−1.35K$10.13−$13.7K−0.7%198.6K after
Nov 23, 2022 (view filing)Nov 212 daysGoeddel David VDirector, 10% OwnerPPurchase+9.62M$2.60+$25.0MNew position9.62M after
Nov 23, 2022 (view filing)4:12 PM ETNov 212 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+9.62M$2.60+$25.0MNew position9.62M afterDuplicate filing
Nov 25, 2022 (view filing)7:05 PM ETNov 178 daysLateCasdin Capital, LLC and 1 otherDirectorPPurchase+2.49M$2.60+$6.48M+69.5%6.08M after
Nov 25, 2022 (view filing)7:05 PM ETNov 178 daysLateCasdin Capital, LLC and 1 otherDirectorPPurchase+1.35M$2.60+$3.52M–1.35M afterDerivative
Dec 9, 2022 (view filing)Nov 2118 daysLateSrivastava DeepakDirectorPPurchase+230.8K$2.60+$600.0K+162.9%372.4K after
Jan 19, 2023 (view filing)Jan 17-182 daysGoeddel David VDirector, 10% OwnerPPurchase+185.2K$2.51+$465.1K+1.9%9.80M after2 lots
Jan 19, 2023 (view filing)4:18 PM ETJan 17-182 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+185.2K$2.51+$464.8K+1.9%9.80M after2 lots
Jan 23, 2023 (view filing)Jan 194 daysGoeddel David VDirector, 10% OwnerPPurchase+69.7K$2.50+$174.3K+0.7%9.87M after
Jan 23, 2023 (view filing)4:25 PM ETJan 194 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+69.7K$2.50+$174.2K+0.7%9.87M after
Feb 10, 2023 (view filing)Feb 82 daysGoeddel David VDirector, 10% OwnerPPurchase+1.50M$2.60+$3.90M+15.2%11.4M after
Feb 10, 2023 (view filing)4:32 PM ETFeb 82 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+1.50M$2.60+$3.90M+15.2%11.4M afterDuplicate filing
Mar 14, 2023 (view filing)Mar 104 daysGoeddel David VDirector, 10% OwnerPPurchase+6.78K$2.60+$17.6K+0.1%11.4M after
Mar 14, 2023 (view filing)4:12 PM ETMar 104 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+6.78K$2.60+$17.6K+0.1%11.4M after
Aug 18, 2023 (view filing)Aug 162 daysAli FarazChief Executive OfficerSSale−5.56K$3.81−$21.2K−4.5%119.4K after
Aug 18, 2023 (view filing)Aug 162 daysPatterson Leone DChief Fin. and Bus. OfficerSSale−4.45K$3.81−$17.0K−6.5%64.5K after
Aug 18, 2023 (view filing)Aug 162 daysTingley WhittemoreChief Medical OfficerSSale−5.56K$3.81−$21.2K−6.8%76.4K after
Aug 18, 2023 (view filing)Aug 162 daysHoey TimothyChief Scientific OfficerSSale−4.01K$3.81−$15.3K−1.5%254.6K after
Aug 29, 2023 (view filing)Aug 29Same dayHoey TimothyChief Scientific OfficerSSale−7.24K$4.26−$30.9K−2.8%247.4K after10b5-1
Feb 14, 2024 (view filing)Feb 122 daysGoeddel David VDirector, 10% OwnerPPurchase+2.22M$4.50+$10.0M+19.5%13.6M after
Feb 14, 2024 (view filing)4:15 PM ETFeb 122 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+2.22M$4.50+$10.0M+19.5%13.6M afterDuplicate filing
Feb 16, 2024 (view filing)Feb 16Same dayAli FarazChief Executive OfficerSSale−6.36K$5.86−$37.3K−5.3%113.1K after
Feb 16, 2024 (view filing)Feb 16Same dayPatterson Leone DChief Fin. and Bus. OfficerSSale−5.20K$5.86−$30.5K−7.9%60.8K after
Feb 16, 2024 (view filing)Feb 16Same dayTingley WhittemoreChief Medical OfficerSSale−6.50K$5.86−$38.1K−8.1%73.5K after
Feb 16, 2024 (view filing)Feb 16Same dayHoey TimothyChief Scientific OfficerSSale−4.68K$5.86−$27.4K−1.9%242.7K after
Feb 21, 2024 (view filing)Feb 201 dayHoey TimothyChief Scientific OfficerSSale−6.57K$5.34−$35.1K−2.7%236.1K after2 lots10b5-1
Mar 6, 2024 (view filing)Mar 51 dayHoey TimothyChief Scientific OfficerSSale−3.30K$7.00−$23.1K−1.3%245.3K after10b5-1
Aug 16, 2024 (view filing)Aug 16Same dayAli FarazChief Executive OfficerSSale−9.75K$2.89−$28.2K−4.9%188.3K after2 lots
Aug 16, 2024 (view filing)Aug 16Same dayTingley WhittemoreChief Medical OfficerSSale−7.43K$2.89−$21.5K−6.5%107.1K after2 lots
Aug 19, 2024 (view filing)Aug 163 daysSaito ChihiroSVP, Accounting and Fin. Ops.SSale−2.36K$2.89−$6.83K−3.6%63.2K after3 lots
Nov 18, 2024 (view filing)Nov 18Same daySaito ChihiroSVP, Accounting and Fin. Ops.SSale−2.26K$2.12−$4.79K−3.6%61.0K after
Mar 7, 2025 (view filing)Mar 52 daysGoeddel David VDirector, 10% OwnerPPurchase+35.7M$0.70+$25.0M+262.6%49.3M after
Mar 7, 2025 (view filing)Mar 52 daysGoeddel David VDirector, 10% OwnerPPurchase+53.6M–––17.9M afterDerivative2 lots
Mar 7, 2025 (view filing)7:14 PM ETMar 52 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+35.7M$0.70+$25.0M+262.6%49.3M afterDuplicate filing
Mar 7, 2025 (view filing)7:14 PM ETMar 52 daysColumn Group III-A, LP and 5 others10% OwnerPPurchase+53.6M–––17.9M afterDerivative2 lotsDuplicate filing
Mar 10, 2025 (view filing)Mar 10Same dayAli FarazChief Executive OfficerSSale−9.74K$0.54−$5.26K−2.9%320.5K after2 lots
Mar 10, 2025 (view filing)Mar 10Same dayTingley WhittemoreChief Medical OfficerSSale−7.40K$0.54−$3.99K−4.1%174.8K after3 lots
Mar 10, 2025 (view filing)Mar 10Same dayHiga TomohiroSVP, FinanceSSale−2.48K$0.54−$1.34K−2.4%99.7K after3 lots
May 16, 2025 (view filing)7:07 PM ETMay 16Same dayAli FarazChief Executive OfficerSSale−3.19K$0.4427−$1.41K−1.0%317.3K after
May 16, 2025 (view filing)7:07 PM ETMay 16Same dayTingley WhittemoreChief Medical OfficerSSale−2.94K$0.4427−$1.30K−1.7%171.9K after
May 16, 2025 (view filing)7:07 PM ETMay 16Same dayHiga TomohiroSVP, FinanceSSale−1.39K$0.4427−$615.35−1.4%98.3K after
Aug 18, 2025 (view filing)Aug 18Same dayHiga TomohiroSVP, FinanceSSale−2.96K$1.25−$3.70K−3.0%95.3K after3 lots
Aug 18, 2025 (view filing)Aug 18Same dayAli FarazChief Executive OfficerSSale−14.5K$1.25−$18.2K−4.6%302.8K after3 lots
Aug 18, 2025 (view filing)Aug 18Same dayTingley WhittemoreChief Medical OfficerSSale−5.05K$1.25−$6.32K−2.8%172.8K after3 lots
Nov 17, 2025 (view filing)Nov 17Same dayAli FarazChief Executive OfficerSSale−3.13K$1.33−$4.16K−1.0%299.7K after
Nov 17, 2025 (view filing)Nov 17Same dayTingley WhittemoreChief Medical OfficerSSale−2.88K$1.33−$3.83K−1.7%169.9K after
Nov 17, 2025 (view filing)Nov 17Same dayHiga TomohiroSVP, FinanceSSale−1.37K$1.33−$1.82K−1.4%94.0K after
Feb 12, 2026 (view filing)5:19 PM ETFeb 10-112 daysSvennilson Peter and 7 others10% OwnerSSale−4.40M$0.6914−$3.04M−62.4%2.65M after4 lots